{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:50:48Z","timestamp":1793224248816,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.esmoop.2026.107735","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:40:00Z","timestamp":1779900000000},"page":"107735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib\u2013fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-6533","authenticated-orcid":false,"given":"S.-A.","family":"Im","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-7902","authenticated-orcid":false,"given":"K.","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.L.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-4958","authenticated-orcid":false,"given":"S.","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-9171","authenticated-orcid":false,"given":"S.","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-0336","authenticated-orcid":false,"given":"E.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Karadurmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8552-6831","authenticated-orcid":false,"given":"A.A.","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2796-1042","authenticated-orcid":false,"given":"E.M.","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-F.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Thanopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Juric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2026.107735_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/2159-8290.CD-21-0072","article-title":"RTK-dependent inducible degradation of mutant PI3K\u03b1 drives GDC-0077 (inavolisib) efficacy","volume":"12","author":"Song","year":"2022","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.esmoop.2026.107735_bib2","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107735_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.107735_bib4","author":"Juric","year":"2024"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107735_bib5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107735_bib6","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107735_bib7","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","article-title":"Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial","volume":"18","author":"Rugo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107735_bib8","doi-asserted-by":"crossref","first-page":"317.e11","DOI":"10.1016\/j.amjmed.2017.09.044","article-title":"Sulfonylureas as initial treatment for type 2 diabetes and the risk of severe hypoglycemia","volume":"131","author":"Yu","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.esmoop.2026.107735_bib9","author":"Saura","year":"2024"},{"key":"10.1016\/j.esmoop.2026.107735_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2018.05.017","article-title":"Palbociclib plus endocrine therapy in older women with HR+\/HER2\u2212 advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies","volume":"101","author":"Rugo","year":"2018","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1016\/j.esmoop.2026.107735_bib11","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.24.00110","article-title":"Phase I\/Ib trial of inavolisib plus palbociclib and endocrine therapy for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer","volume":"42","author":"Jhaveri","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107735_bib12","author":"Oliveira","year":"2025"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107735_bib13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","article-title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer","volume":"31","author":"Rugo","year":"2020","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:30:42Z","timestamp":1781868642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926016777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2059702926016777"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107735","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib\u2013fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107735"}}